CATB - Catabasis Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue-500--
Cost of Revenue----
Gross Profit-500--
Operating Expenses
Research Development15,63217,41324,43122,202
Selling General and Administrative9,83910,18111,1279,457
Non Recurring----
Total Operating Expenses25,47127,59435,55831,659
Operating Income or Loss-25,471-27,094-35,558-31,659
Income from Continuing Operations
Total Other Income/Expenses Net-399-270-502-971
Earnings Before Interest and Taxes-25,471-27,094-35,558-31,659
Interest Expense-100-462-837-978
Income Before Tax-25,870-27,364-36,060-32,630
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-25,870-27,364-36,060-32,630
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-25,870-27,364-36,060-32,630
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-25,870-27,364-36,060-32,630